Theravance Biopharma (TBPH) Common Equity (2016 - 2025)
Historic Common Equity for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $232.7 million.
- Theravance Biopharma's Common Equity rose 2533.05% to $232.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.7 million, marking a year-over-year increase of 2533.05%. This contributed to the annual value of $175.5 million for FY2024, which is 1758.26% down from last year.
- As of Q3 2025, Theravance Biopharma's Common Equity stood at $232.7 million, which was up 2533.05% from $224.8 million recorded in Q2 2025.
- Theravance Biopharma's Common Equity's 5-year high stood at $480.6 million during Q3 2022, with a 5-year trough of -$373.2 million in Q1 2021.
- Its 5-year average for Common Equity is $72.6 million, with a median of $193.7 million in 2024.
- Per our database at Business Quant, Theravance Biopharma's Common Equity tumbled by 13630.96% in 2021 and then skyrocketed by 24851.36% in 2022.
- Quarter analysis of 5 years shows Theravance Biopharma's Common Equity stood at -$338.6 million in 2021, then surged by 230.49% to $441.8 million in 2022, then plummeted by 51.79% to $213.0 million in 2023, then fell by 17.58% to $175.5 million in 2024, then surged by 32.55% to $232.7 million in 2025.
- Its Common Equity stands at $232.7 million for Q3 2025, versus $224.8 million for Q2 2025 and $166.0 million for Q1 2025.